Wall Street brokerages expect Alliqua Biomedical Inc (NASDAQ:ALQA) to post earnings per share of ($0.02) for the current quarter, Zacks Investment Research reports. Zero analysts have issued estimates for Alliqua Biomedical’s earnings. Alliqua Biomedical reported earnings of ($0.79) per share in the same quarter last year, which would indicate a positive year over year growth rate of 97.5%. The firm is expected to report its next quarterly earnings report on Thursday, November 8th.
According to Zacks, analysts expect that Alliqua Biomedical will report full year earnings of $5.14 per share for the current financial year. For the next financial year, analysts anticipate that the company will post earnings of ($0.09) per share. Zacks Investment Research’s earnings per share calculations are an average based on a survey of research analysts that that provide coverage for Alliqua Biomedical.
Alliqua Biomedical (NASDAQ:ALQA) last released its quarterly earnings data on Friday, August 10th. The company reported ($0.66) EPS for the quarter, missing the Zacks’ consensus estimate of ($0.02) by ($0.64). The business had revenue of $0.86 million during the quarter. Alliqua Biomedical had a negative net margin of 90.48% and a negative return on equity of 235.69%.
A hedge fund recently bought a new stake in Alliqua Biomedical stock. FNY Investment Advisers LLC purchased a new stake in Alliqua Biomedical Inc (NASDAQ:ALQA) in the 3rd quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor purchased 200,000 shares of the company’s stock, valued at approximately $454,000. FNY Investment Advisers LLC owned 3.99% of Alliqua Biomedical at the end of the most recent reporting period. 17.68% of the stock is owned by institutional investors and hedge funds.
ALQA stock traded down $0.04 during mid-day trading on Thursday, reaching $1.70. The company’s stock had a trading volume of 5,705 shares, compared to its average volume of 25,309. Alliqua Biomedical has a fifty-two week low of $1.55 and a fifty-two week high of $3.85.
About Alliqua Biomedical
Alliqua BioMedical, Inc, a regenerative technologies company, commercializes regenerative medical products that assist the body in the repair or replacement of soft tissue. The company markets MIST Ultrasound Healing Therapy, a painless noncontact low-frequency ultrasound to promote healing; and Biovance Amniotic Membrane Allograft and Interfyl Human Connective Tissue Matrix, which are human biologic regenerative technologies.
Featured Story: Outstanding Shares
Get a free copy of the Zacks research report on Alliqua Biomedical (ALQA)
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Alliqua Biomedical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alliqua Biomedical and related companies with MarketBeat.com's FREE daily email newsletter.